Description
Supercharge your metabolic studies with Retatrutide, the groundbreaking, next-generation triple agonist engineered to push the boundaries of energy expenditure and weight-regulation research.
🚀 Retatrutide: The Next-Gen Triple Agonist Powerhouse
Leave dual agonists behind. While tirzepatide stops at GIP and GLP-1, Retatrutide shatters limitations by targeting three distinct metabolic pathways: GIP, GLP-1, and Glucagon. This sophisticated triple-agonist profile allows you to investigate the ultimate combined synergy of glucose metabolism, deep appetite signaling, and lipid breakdown.
💎 Unmatched Purity & Lab Performance
- Flexible 15-30 mg Yield: Every single 3 mL vial delivers a yield of 15-30 mg concentration of lyophilized Retatrutide to maximize your testing timeline.
- Triple Receptor Synergy: The definitive model for next-level research into energy expenditure, intensive body-weight regulation, and lipid metabolism.
- Extensively Researched: Tap into one of the most thoroughly investigated, next-generation metabolic peptides currently in global development.
- Premium Stability: Formulated as a highly stable lyophilized powder, optimized for seamless reconstitution with Bacteriostatic (BAC) Water.
COA AVAILABLE
Research Use Only. Not for Human or Veterinary Use. These products are not intended to diagnose, treat, cure, or prevent any disease. Product information is provided for research and educational purposes only.
Reviews
There are no reviews yet.